Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells by Harada, Yui et al.
Cytokine-basedhighlog-scaleexpansion
of functional human dendritic cells from
cord-blood CD34-positive cells
Yui Harada
1,2,3, Yae Okada-Nakanishi
3, Yasuji Ueda
2,5, Shunichi Tsujitani
4, Satoru Saito
2,3,
Terumi Fuji-Ogawa
2, Akihiro Iida
5, Mamoru Hasegawa
5, Tomohiko Ichikawa
1 & Yoshikazu Yonemitsu
2,3
1DepartmentsofUrology,ChibaUniversityGraduateSchoolofMedicine,Chiba260-8670,Japan,
2Department ofGeneTherapy,
Chiba University Graduate School of Medicine, Chiba, Japan,
3R&D Laboratory for Innovative Biotherapeutics, Kyushu University
GraduateSchoolofPharmaceuticalSciences,Fukuoka812-8582,Japan,
4DepartmentofSurgeryandScience,GraduateSchoolof
Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan,
5DNAVEC Corporation, Tsukuba, Ibaraki, Japan.
Dendritic cells (DCs) play a crucial role in maintaining the immune system. Though DC-based cancer
immunotherapy has been suggested as a potential treatment for various kinds of malignancies, its clinical
efficacies are still insufficient in many human trials. Issues that limit the clinical efficacy of DC-based
immunotherapy, as well as the difficulty of the industrial production of DCs, are largely due to the limited
number of autologous DCs available from each patient. We here established a possible breakthrough, a
simple cytokine-based culture method to expand the log-scale order of functional human DCs. Floating
cultivation of cord-blood CD34
1 cells under an optimized cytokine cocktail led these progenitor cells to
stable log-scale proliferation and to DC differentiation. The expanded DCs had typical features of
conventional myeloidDCs in vitro. Therefore, the concept of DC expansionshould contribute significantly
to the progress of DC immunotherapy.
T
he World Health Organization’s Global Burden of Disease statistics identified cancer as the second-largest
global cause of death after cardiovascular disease, and predicted that the number of cancer patients would
increase
1. Although advances in the prevention, diagnostics, and treatment of cancer have improved pro-
gnoses for cancerpatients,cancerisstill refractory.Wethusneed astrongnew therapyfor advancedmalignancies.
Dendritic cells (DCs) have received much attention as a new therapeutic tool for cancer immunotherapy
against advanced malignancies. DCs are unique antigen-presenting cells that can efficiently stimulate innate as
well as acquired immune responses against pathogens and endogenous cancers. In the past decade, DC-based
immunotherapy has been expected to serve as a new therapeutic modality for cancers and infectious diseases.
However, relatively limited efficacies have been reported intheir clinical studies
2.Complex issues, aconsequence
of too many variables in current clinical studies, must be solved in order to standardize DC-immunotherapy,
includingDCsubtypes,antigentargetinginvivo,dosesofDCs,andsoon
3.Amongtheseparameters,thepossible
critical issue underlying DC-immunotherapy is that limited numbers of DCs (roughly 10
6 to 10
8) are available
from each patient in clinical studies, even via frequent aphereses for DC progenitor collection
4. In our experi-
mental studies on the use of dermal tumor and lung metastasis models, DC-based immunotherapy showed a
significant dose response; the optimal dose in both models was at least 10
6 DCs/30 g, roughly equivalent to 10
9
DCsperpatientaccordingtotheweightratio
5,6.Moreover,Provenge,thefirstFDA-approvedautologouscellular
therapy, showed a therapeutic outcome in which the median time to disease progression was 31.7 weeks for
patients who received more than 1x10
8 cells per infusion, compared with 12.1 weeks for patients who received
fewer cells (p50.013)
7. Therefore, increasing the number of DCsis expected toimprove the efficacy of DC-based
immunotherapy in clinical settings. In addition, there is a strong desire to develop technology to increase the
number of DCs in order to make the process of DC manipulation less invasive and improve quality control in
industrial production.
We have established and optimized a culture method based on the cytokine cocktail FS36 (Flt3-L, SCF, IL-3,
IL-6) forDCexpansionin mice
8. We proved that the expanded DCs had properties that were necessary to obtain
therapeutic gains--such as the expression of molecules needed for antigen presentation, endocytotic activity, the
potential for inflammatory cytokine/chemokine production, and stimulation activity for allogeneic T-cell pro-
liferation--and also showed significant prevention of hypodermic tumors and experimental lung metastasis
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that murine functional DCs can be efficiently expanded ex vivo by
more than 3 logs. This technology raised an important question: is
the cytokine cocktail used in the study applicable to the expansion of
human DCs? As far as we know, only one study addressing this issue
has been published. This study used a sequential culture of CD34
1
cells in medium containing FS36 followed by an alternative cocktail
(FLT3-L, SCF, and thrombopoietin) and showed a dramatic expan-
sion (453-fold) in the cell number of progenitors; however, only
,1x10
6 DCs were produced from 1x10
5 CD34
1 cells
9. Therefore,
we here focused on the development of a new technique for the
expansion of functional human DCs from cord-blood (CB) CD34
1
cells.
There are some reports about CD34
1 cell-derived DC-based
immunotherapy
10–14. It was reported that TNF-alpha is critical for
the differentiation and maturation of DCs from CD34
1 cells, as it
upregulates the GM-CSF receptor while downregulating receptors
for other lineage-restricted cytokines
15,16. GM-CSF drives the differ-
entiation of monocytes, highly expressing GM-CSF receptor alpha
(CD116) into immature DCs, and monocytes expressing very low
levels of CD116 were shown to be completely refractory to differ-
entiate into DCs and gave rise only to macrophages
17. On the other
hand, the cytokine cocktail GM/IL-4, a general cytokine cocktail for
DC generation without TNF-alpha, could not generate or expand
DCs from CD34
1 cells. However, the combined use of TNF-alpha
andGM-CSFinducedtherapiddifferentiationandactivationofDCs
fromCD34
1cells,sothecellexpansionratewoulddecrease(datanot
shown). We then proposed the combined use of GM-CSF and stem
cell factor (SCF, also known as c-kit ligand). SCF is an early-acting
cytokinethatbindstoreceptorsthathavetyrosinekinaseactivity;itis
expressed on primitive progenitor cells
18. Suspension cultures and
clonogenic assays of human CD34
1 cells both suggest that the addi-
tion of SCF leads to higher DC production than with GM-CSF and
TNF-alpha
19–21. Recently, Balan et al. reported a simple two-step
culture method for DC expansion from CB CD34
1 cells (650-fold).
However, the method contained a cell-selection step and used other
variouscytokines
22.Forclinicaluse,asimplemethodisdesired,sowe
decidedtousesimplecytokinecocktailGM-CSFandSCF(GM/SCF)
for the expansion of DCs and to suppress the rapid activation of
progenitor cells by not using TNF-alpha.
We established an optimized culture system, which provided an
importantadvanceforgeneratingmyeloidDCproductsfromCD34
1
cells with high cell numbers, high purity, and functionality for use in
DC-based immunotherapy for various malignancies.
Results
Kinetics of expansion of CD11c
1 cells from CB CD34
1 cells. DC
expansionregimenisshowninfigure1a.CBCD34
1cells(purity5.
95%) were purchased from Lonza (Switzerland) and cultivated for
several weeks under the optimized cytokine cocktails. CB CD34
1
cells had increased approximately 100,000-fold after 5 weeks of
culture under GM/SCF (Figure 1b). When the cultivation was
started by GM/IL-4, the yielded cells showed low viability and a
low CD11c-positive ratio (data not shown). The CD11c-positive
ratio of proliferating cells during cultivation under GM/SCF gradually
increased, exceeding 80% after 5 weeks’ cultivation (Figure 1c). The
expansion rate tended to slow as the CD11c-positive ratio rose.
Finally, more than 10
10 CD11c
1/CD14
1 cells were obtained from
10
5 CB CD34
1 cells (510
5-fold expansion) after 5 weeks’ cultiva-
tion under GM/SCF (Ex-GSDC) (Figure 1d). More than 10
8 CD11c
1
/CD14
1 cells were obtained from 10
5 mobilized PB CD34
1 cells
(510
3-fold expansion) after 5 weeks’ cultivation under GM/SCF
(Supplementary Figure). Moreover, about 5x10
9 CD11c
1/CD14
-
cells were obtained from 10
5 CB CD34
1 cells (510
4-fold expan-
sion) by one-week cultivation under GM/IL-4 (GM-CSF and IL-4)
after expansion for 4 weeks under GM/SCF (Ex-G4DC) (Figure 1d,
e). Flow cytometric analyses revealed the expression of surface
markers of each DC (Figure 1f). All DCs in this study were posi-
tive formyeloid-associatemarkers(CD11cand CD11b)andnegative
for lymphoid-associate markers (B220 and CD3). Ex-GSDC expressed
E-cadherin (mediated cell–cell adhesion), however, the expression
on Ex-G4 DC and Md-DC were low or negative. These experiments
were repeated at least three times in 3 individuals.
Characterization of expanded CD11c
1 cells. Next, we assessed
whether or not CD11c
1 cells yielded by the expansion method
from CB CD34
1 cells (Ex-GSDC and Ex-G4DC) might meet
typical features of DCs via a conventional culture method (CD14
1
monocyte-derived DC: md-DC).
1)Morphology.Asareseeninmd-DC,typicaldendrites werefound
in both Ex-GSDC and Ex-G4DC under microscope 2 days after
cultivation under medium containing stimulators: lipopolysaccharide
(LPS: 1 mg/ml), OK-432 (0.5 KE/ml), or rSeV/dF (MOI550). rSeV/
dF-activated DCs are shown in Figure 2a.
2) Surface markers. Flow cytometric analyses revealed the expres-
sion of typical surface markers of each DC (Figure 2b and Sup-
plementary Table). Although the expression level of each antigen
varied among the DCs, all types of cells expressed surface markers
needed for antigen presentation and chemokine receptors such as
MHC class II (HLA-DR), CD86, ICAM-1, CCR5, and CCR7. Ex-
pression of MHC Class II was clearly upregulated by rSeV infection.
Ex-GSDC and Ex-G4DC showed higher levels of ICAM-1 expres-
sion than md-DC. All data were analyzed after CD11c-positive
gating.
3) Production of inflammatory cytokines and chemokines. All
types of DCs commonly expressed typical inflammatory cytokines
and chemokines in response to various stimulators, including the F-
gene-deleted non-transmissiblerecombinantSendaivirus(rSeV/dF)
recognized by RIG-I
23, LPS by Toll-like receptor 4 (TLR-4), or
Streptococcal preparation OK-432 (a GMP grade agent for the
functional maturation of DCs) by TLR-4 and b2 integrins
24,25
(Figure 3a). Although Ex-GSDC failed to produce TNF-alpha or
IL-12p70 (needed for Th1 induction), Ex-G4DC expressed these
cytokines as seen in md-DC stimulated by OK-432. Both Ex-DCs
activated by LPS produced lower levels of IL-10 (a cytokine for Th2
induction) than md-DC activated by LPS did. rSeV/dF could not
induce a high production level of each cytokine and chemokine
from all types of DCs, and these findings were similar to those in
our previous study
6,8. rSeV/dF induced spontaneous maturation and
activationofDCs,however,theirphenotypeisnotequaltothoseseen
in the treatment with LPS
26.
4) Endo-/phagocytotic activity. Next, we assessed the endo-/
phagocytotic activity, a typical feature of antigen-presenting cells
like DCs, by an FITC-dextran (M.W. 540,000) uptake assay
(Figure 3b). Repeated experiments demonstrated that each unsti-
mulated immature DC showed similar uptake activity that was
impaired by rSeV/dF infection or LPS, findings similar to those of
our previous study
6. Although a significant decrease in phagocytotic
activity was not seen in Ex-GSDC, a tendency toward a decrease was
seen. Each OK-432-stimulated DC showed higher phagocytotic
activity than those stimulated by rSeV/dF or LPS.
5) T-lymphocyte stimulation activity. The assay for mixed
leukocyte reaction (MLR) against allogeneic antigen (CD3
1 T-cells
from a volunteer) demonstrated the alloantigen-specific T-lympho-
cyte proliferation by each DC stimulated with or without rSeV/dF,
LPS, or OK-432. This, in turn, suggested the stimulating activity
of all types of DCs to alloantigen-specific T-cell proliferation
www.nature.com/scientificreports
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1cell-derivedCD11c
1cells. (a)TheregimenofcellexpansionfromCBCD34
1cells.(b)Growthcurve
oftotalcellsfromCBCD34
1cells.After4weeksofcultivationunderGM/SCF(blackline),culturemediumwassubsequentlyreplacedwithGM/IL-4(red
line)for1week.GM/IL-4couldnotexpandthe cells.(c)CD11c-positiveratiosofexpandedcellsunderGM-CSFandSCF.Theratioofproliferating cells
during cultivation under GM/SCF gradually increased, exceeding 80% after 5 weeks’ cultivation. The cells cultured under GM/IL-4 for a week after 4
weeks’ cultivation under GM/SCF also showed a high CD11c-positive ratio. (d) Growth curve of CD11c
1 cells from CB CD34
1 cells. These experiments
were repeated seven times in 5 individuals (GM/SCF) and three times in 3 individuals (GM/IL-4). (e) The numbers of CD11c
1/CD14
1 and CD11c
1/
CD14
- DC generated from each culture. (f) FACS profiles of the DC products. These experiments were repeated at least three times in 3 individuals.
www.nature.com/scientificreports
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showed strong activity.
Discussion
The ultimate needs for sufficient numbers of functional DCs in clin-
ical settings, in view of both therapeutic efficacy and industrial pro-
duction, have forced us to develop an efficient and representative
method for mass producing functional DCs. We established and
optimized a culture method for DC expansion in mice using a
two-stepculture
8.However,theculturemethodcouldn’tbeextended
to human DC expansion. We then established and optimized a new
culture method for human DC expansion: a 5-week expansion and
differentiation under GM-CSF and SCF (GM/SCF); and a two-step
culture method: a 4-week expansion and differentiation under GM/
SCFfollowedbyoneweekofcultivationunderGM/IL-4.Theexpan-
sion rates varied according to the cell sources. The cells showing
greater expansion were CB CD34
1 cells; they increased approxi-
mately 100,000-fold after 5 weeks of culture, and .80% of expanded
cells expressed CD11c. To the best of our knowledge, this is the first
demonstrationthathumanfunctionalDCsderivedfromCD34
1cells
can be efficiently expanded ex vivo by more than 5-logs. In some
clinical reports, the administration of 1x10
7 DCs waseffective
27,28,s o
the administration of 1x10
8 DCs (10-fold of the present clinical dose
innumber)maybesufficienttoimprovetherapeuticoutcomes.Even
so, a DC-expansion method is important for the preparation of
vaccinations in large quantities.
As are seen in conventional DCs, these expanded DCs showed
dendrites after maturation and endocytotic activities. Expanded
DCs also expressed HLA-DR, adhesion molecules, and co-stimula-
tory molecules and produced inflammatory cytokines/chemokines
as well as conventional DCs did. However, the DCs failed to up-
regulate some antigens following addition of each stimulator.
Obermajer N. et al. reported that maturation coincides with the
de-adhesion of DCs and formation of cell clusters
29. Our all culture
systems are ‘‘floating cultivation’’ using MPC-treatment plates.
Therefore,weconsiderthateachDCinthisstudymaydifferentfrom
conventional‘‘adherent’’DCsandbeactivated.Inaddition,thecyto-
kines produced by each DC generated from different culture condi-
tionsarequitedifferent.Wehavereportedthattheresponsesofsome
cytokines including IL-12/p70 and TNF-alpha to rSeV/dF recog-
nized by RIG-I, LPS by TLR4, poly I:C by TLR3, CpG-DNA by
Figure 2 | In vitro characterization of expanded human DCs. (a) Morphology of rSeV-activated DCs. Wright-Giemsa–stained cytocentrifuge
preparations are shown. Bars in panels530 um. (b) FACS analyses assessing the expression of typical surface markers. DCs with or without further
stimulus were subjected to FACS analyses. A bar graph indicating the corresponding mean fluorescent intensity (MFI) containing data from four
independent experiments is shown.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 1 : 174 | DOI: 10.1038/srep00174 4Figure 3 | Assessment of functions that are typically seen in DCs. (a) Expression of typical human inflammatory cytokines/chemokines of monocyte-
derived DCs and expanded DCs in response to various stimuli. These six panels were assessed by the Cytometric Bead Array (CBA) system and contain
data from three independent experiments. (b) FITC-dextran uptake assay assessing endo-/phagocytotic activity, a typical feature of antigen-presenting
cellslikeDCs.DCswerestimulatedbyeachstimulusandthenexposedto1 mg/mlofFITC–dextranfor30 minat4or37degreesCelsius.Theuptakewas
expressedMFIbetweencellsamplesincubatedat37and4degreesCelsius.Thisexperimentwasperformedthreetimes.(c)AgraphshowingMLRactivity
for allo-antigen by each immature DC or activated DC by SeV/dF, LPS, or OK-432. This experiment was performed three times.
www.nature.com/scientificreports
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different culture system (non-adherent, expansion or conventional
methods)
8. These data suggested that the cytokines produced by DC
might be in accordance with the expression patterns of the receptors
(i.e. TLRs) on DCs.
Additionally,therearesomereportsthatOK-432butLPSstrongly
stimulates DCs to secrete Th1 cytokine (IL-12p70) without Th2
cytokine (IL-10) production
30,31. These data suggested that DCs
stimulated with OK-432 might have favorable characteristics to
induce CTLs specific to antigen peptide. Because of high induction
of Th1 cytokines and low induction of Th2 cytokines, our data also
suggested that OK-432 might show the best clinical efficacy among
activators tested.
Ex-GSDC and Ex-G4DC showed higher ICAM-1 expression than
did md-DC. ICAM-1 (Inter-Cellular Adhesion Molecule 1), also
known as CD54, binds to macrophage adhesion ligand-1 (Mac-1),
leukocyte function-associated antigen-1 (LFA-1), and fibrinogen.
These three proteins are generally expressed on endothelial cells
andleukocytes,andtheybindtoICAM-1tofacilitatetransmigration
acrossvascular endothelia inprocesses such asextravasation and the
inflammatory response. The classical definition of the immuno-
logical synapses is based on a cell–cell interface in which LFA-1–
ICAM-1interactionsandtalinformaringaroundacentralclusterof
TCR–MHCp (T-cell receptor–major histocompatibility complex
molecule–peptide complex) interactions and protein kinase C-h
32–35.
Moreover,according to a reportby Eric J. Small et al., they correlated
the expression of costimulatory molecules with potency in the allo-
MLR in 81 consecutive lots of Provenge and found that potency
correlated most strongly with CD54 expression. In addition, cell-
sorting experiments revealed that all antigen-presenting activity
resided in the CD54
1 population. Based on these observations, they
selected CD54 expression as a marker of dendritic cells and product
potency
7. High ICAM-1 expression levels would support the stabi-
lized and more efficient interaction between DC and T lymphocyte
in vivo.
Functionally, the mixed lymphocyte reaction (MLR) assay
revealed that expanded DCs could stimulate allogeneic T-cell prolif-
eration to the same extent as conventional DCs. Taking these find-
ings together, we concluded that cells expanded and differentiated
from CB CD34
1 cells could be categorized into functional DCs
nearly equivalent to those obtained from the conventional method.
In addition, we succeeded in expanding the CD11c
1 cells from
enriched monocyte by cultivation under GM/SCF (data not shown).
Several studies have assessed the expansive ability of cytokines for
DCs from CD34
1 cells. However, as far as we know, the most recent
study attempting to expand human DCs was published in 2009 by
Balan et al., who used a relatively complex cocktail of cytokines
(GM-CSF, TNF-alpha, IL-4, TPO, SCF, and FLT3-L) and two-step
cultivation containing a monocyte selection step
22. Clinical use
necessitates a simple culture system without complex steps such as
a magnetic-bead method for selecting cells, flow cytometry-cell sort-
ing, or adherent selection. Although others reported some methods
for DC induction from CD34
1 cells without cell selection, the purity
of DC was relatively low (,50–60%)
7,11,12,36–38, whereas our method
broke through this problem (.80%). For mass production and qual-
ity control, a ‘‘DC bank’’ based on the cord-blood bank could be
established.
Wedemonstrated thatexpanded DCsshowedcharacteristics that,
fromthestandpointsofmorphology,surfacemarkers,andbiological
functions in vitro, were similar to those seen in conventional DCs. If
CTLs were the main effector of DC-based immunotherapy against
cancer, Ex-G4DC activated by OK-432 might show the best clinical
efficacy among these expanded DCs because the cells produced IL-
12p70 and showed strong T-lymphocyte stimulation activity.
However, we reported that the main effector of antitumor immunity
is CD4
1 T cells and NK cells
39. Upon administration, the vaccine is
thoughttoinduceanantigen-specificT-cellresponseandNKactiva-
tionagainstthetumor.Thetherapeutic gainsof bothexpanded DCs,
Ex-GSDC and Ex-G4DC, have to be assessed.
A problem that needs to be solved for clinical use is that the
expanded DCs yielded from CB CD34
1 cells were generally allo-
geneic to patients. Though some reported that allogeneic DCs were
effective, autologous DCs were needed to achieve efficient clinical
efficacies
40,41 and safety. Although we could also expand DCs from
PB CD34
1 cells (3-log), the number of DCs might not be enough to
treat various malignancies because of very low numbers of CD34
1
cells andthedifficulty ofcollecting asufficient number of progenitor
cells. To obtain a sufficient number of DCs, we attempted to extend
this expansion method using CD34
1 cells to expansion from peri-
pheral blood mononuclear cells (PBMCs). We then succeeded in
expanding DCs from PBMC by an easy new method that achieved
an expansion rate 5 , 1x10
7 DCs from 1 ml PB (patent pending).
In summary, we here report optimized one-step and two-step
culture methods to generate highly expanded functional myeloid
DCs from CB CD34
1 cells. The concept and technology of log-scale
expansion of functional DCs would significantly contribute not only
to improved therapeutic efficacies but also to industrial mass pro-
duction of functional autologous DCs for more efficient DC-based
immunotherapy. DC expansion technology will improve cancer
therapies and alleviate patients’ burden of apheresis.
We should optimize other parameters of the DC vaccine and
enhance the development of immunotherapy. In addition, future
clinical studies should utilize standard criteria for clinical response
and require validation in increased numbers of patients.
Methods
Cells and rSeV/dF. Human cord-blood (CB) CD34
1 cells were purchased from
Lonza (Switzerland). The preparation, recovery, titration, and storage of F-defective
and non-transmissiblerecombinant SeV usedin this study (SeV/dF) were performed
as previously described
42. Virus yield is expressed in cell infectious units (CIU)
42,43.
Generation of expanded DCs. Conventional DCs were obtained from peripheral
blood CD14
1 cells as described previously, with minor modification. Briefly, CD14
1
cells were cultured under GM/IL-4 (100 ng/ml GM-CSF and 50 ng/ml IL-4) in
IMDM medium containing 10% FBS and 1% penicillin and streptomycin. CD14
1
monocytes were obtained by negative selection. Briefly, peripheral blood
mononuclear cells (PBMC) were obtained using a Ficoll gradient separation
purchasedfromtheAustralian RedCrossBloodService(Melbourne,Vic., Australia).
Cells were washed in PBS, and lineage antigen-positive (CD2, CD3, CD19, CD20,
CD56, CD66b, CD123, Glycophorin A) cells were removed by using the EasySep
human monocyte enrichment kit without CD16 depletion (StemCell Technologies,
Canada). These lineage-negative CD14
1 cells were cultured under 100 ng/ml human
GM-CSF (Peprotech, USA) and 50 ng/ml human IL-4 (Peprotech) in IMDM
medium. Each cytokine was dissolved in PBS containing 0.1% BSA in 100 times the
density used. For expansion, CD34
1 cells were cultured under GM/SCF (100 ng/ml
GM-CSFand50 ng/mlSCF)orGM/IL-4(100 ng/mlGM-CSFand50 ng/mlIL-4)in
IMDMmedium.Themediumwasexchangedevery3or4days.Cellswereculturedin
the MPC treatment plate (MD6 with Lid Low-Cell Binding; Nalge Nunc
International, Japan).
Wright-Giemsastaining.TheDCsweremorphologicallyassessedusingtheWright-
Giemsa staining method. Cells were prepared on slides by Cytospin (Shandon
Southern, UK) and stained with Wright-Giemsa stain. The cell morphology was
examined under a light microscope.
Flow cytometric analysis. After 5 week’s cultivation or 2 days after stimulation,
cells (1310
5) were stained with the following FITC-, PE-, or PE-Cy5-conjugated
monoclonal antibodies (mAbs): CD1a, CD1d, CD3, CD11b, CD11c, CD14, CD33,
CD40, CD45R (B220), CD54 (ICAM-1), CD80, CD83, CD86, CD123 (IL-3Ra),
CD195 (CCR5), CD197 (CCR7), CD207 (Langerin), CD324 (E-cadherin), HLA-
ABC, HLA-DR (Pharmingen, USA). The appropriate conjugated isotype-matched
IgGs were used as controls. Cells were analyzed using FACScalibur with the use of
CellQuest software (Becton Dickinson, USA).
Fluoresceinisothiocyanate(FITC)-dextranuptake.CellsweresuspendedinIMDM
with10%FBSandincubatedwith1 mg/mlofFITC-dextran(M.W.540,000,Sigma-
Aldrich, Tokyo, Japan) for 30 min under separate conditions, at 4
oC and 37
oC. The
cells were washed three times with ice-cold phosphate-buffered saline (PBS) and
labeledonicewithPE-conjugatedmAbforCD11c.CD11c-positivemeanfluorescent
intensity (MFI) of FITC was analyzed by FACScalibur. The uptake was measured at
www.nature.com/scientificreports
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incubated at 37
oC and those incubated at 4
oC.
Allogeneic mixed leukocyte reactions (allo-MLRs). Allogeneic CD3
1 T-cells were
obtained from a volunteer. After Ficoll separation (GE Healthcare Bio-Sciences AB,
Sweden), cell surface antigen-positive (CD14, CD16, CD19, CD56, glycophorin A)
cells were removed by using the EasySep Human T-Cell Enrichment kit (StemCell
Technologies, Canada); these served as responder cells. In-vitro-generated immature
expanded DCs, as well as rSeV/dF-DCs, LPS-DCs, and OK-432-DCs stimulated on
day35,werecollectedonday37.TheseDCsweretreatedwith20 ug/mlMitomycinC
(MMC) for 1 hour at 37
oC and then used as stimulator cells. Allogeneic responder
cells (1310
5 cells/wells) were cultured in duplicate or triplicate in a 96-well round-
bottom microplate with different numbers of stimulator APCs (APC-to-T cell ratios
were 1510, 15100, and 151000). Cultures were maintained in a humidified
atmosphere at 37
oC and 5% CO2. The thymidine analogue BrdU was added on day 4
followedbyquantitationofincorporatedBrdUafterafurther2 hoursofcultureusing
an ELISA-based cell proliferation kit (BrdU colorimetric, 1647229, Roche,Germany)
according to the manufacturer’s protocol.
Cytokine assay. The conventional/expanded DCs were cultured with rSeV/dF
(MOI 5 50), LPS (1 ug/ml), or OK-432 (0.5 KE/ml) for 2 days. The culture media
were subjected to concentrations of human IL-1 beta, IL-6, IL-8, IL-10, IL-12p70,
and TNF-alpha by the Cytometric Bead Array (CBA) Human Inflammation Kit
(BD Biosciences, USA) using FACScalibur with the use of CellQuest software
(Becton Dickinson, USA).
Statistical analysis. All data were expressed as the mean 6 SEM and were evaluated
statistically by one-way ANOVA. The statistical significance of differences was
determined using the Dunnett’s test, and P,0.05 was considered statistically
significant.
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